{"acquisitions":[],"changes":[],"country":"US","description":"Xaira Therapeutics combines generative AI drug discovery with wet-lab biology to design novel small molecules and biologics. The company targets oncology, immunology, and rare-disease indications across multiple modalities. Founders span Stanford's protein-design group, ARCH Venture Partners, and Foresite Labs.","domain":"xaira.com","employees":null,"founded":2024,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":37.65904,"lng":-122.396451,"location":"San Francisco, USA","multiples":[],"name":"Xaira Therapeutics","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":1000000000,"connectionsAmong":[],"currency":"USD","date":"2024-04-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"xaira-com-2024-04-01-series-a","source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-04-29","status":"attributed","url":null},"status":"attributed","type":"series-a","url":null}],"slug":"xaira-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-04-29","status":"attributed","url":null},{"fact":"existence","publisher":"xaira.com","retrievedAt":"2026-04-29","status":"self-reported","url":"https://xaira.com"},{"fact":"description","publisher":"xaira.com","retrievedAt":"2026-04-29","status":"self-reported","url":"https://xaira.com"}],"stage":"series-a","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":["Cloudflare","jsDelivr","cdnjs","OneTrust","jquery 3.5.1"],"totalRaisedUsd":1000000000,"traction":[],"updatedAt":"2026-04-29","valuations":[]}